The Science and Business of Drug Discovery

 

Dedication

Acknowledgements

Preface

1 Introduction

Part I

How drugs are discovered and developed in the pharmaceutical industry

2 Introduction to drugs and drug targets

 

3 Background to chemistry of small and large molecules

 

4 Laying the foundations- Drug discovery from antiquity to the twenty first century

Part II

The drug development pipeline - discovery to testing in humans

 5 Drug discovery pipeline overview



6 Target discovery

7 Medicinal chemistry

8 Biotherapeutics

9 Screening for hits

10 Process chemistry and formulation

11 Preclinical development

Part IIIThe drug development pipeline - clinical trials to marketing authorisation



 

12 Clinical trials

13 Regulatory affairs and marketing approval

14 Diagnostics and personalized medicine

15 Putting it All Together: a drug development case history

Part IV The Global Pharmaceuticals Business



 

16 Commercial aspects of drug development

17 Challenges and responses




Part V


Professional Interactions with the Drug Discovery Industry




18 Professional Interactions with the Drug Discovery Industry: Technology Transfer Executives

19 Recruitment Executives

20 Pharmaceutical translators and Interpreters

 

Appendix 1 Further Reading

 

Appendix 2 Glossary of terms

Dr. Edward D. Zanders has over 30 years' experience as a scientist and research manager in both a major pharmaceutical company and in smaller biotechnology organizations. He has been responsible for a number of drug discovery programs for diseases such as asthma and rheumatoid arthritis and has been involved in research management at a senior level. He has also published extensively on subjects ranging from biochemistry and immunology to computer-aided drug design and the application of online networking to drug discovery. More recently he has written about drug targets in the human genome and a survey of drug discovery for glioblastoma. In 2004 he founded PharmaGuide Ltd, a training and consultancy company that delivers courses on the drug discovery industry to various professional groups including technology transfer executives, recruiters and technical translators. It is through delivering these courses that he has been able to develop his own way of conveying complex information about drug discovery to non scientists, while at the same time being able to communicate with PhD level scientists at their level of expertise.